Licensing status

Publication and contact information


Graft-versus-host disease (GvHD)

Delta-like 1 (DLL1); DLL4

Mouse studies suggest mAbs against DLL1 and DLL4 could be useful for preventing GvHD. In a mouse model for GvHD, transient treatment with mAbs against Dll1 and Dll4 decreased disease severity and increased survival compared with control mAbs. Next steps include characterizing the long-term effects of the anti-DLL1/DLL4 mAbs.
The Genentech Inc. unit of Roche collaborated on the study but has not disclosed whether it has an anti-DLL1/DLL4 mAb in preclinical development.
At least four companies have compounds targeting DLL4 in Phase I testing or earlier to treat various cancers.

SciBX 6(12); doi:10.1038/scibx.2013.295
Published online March 28, 2013

Patents filed by Genentech; licensing status undisclosed

Tran, I.T. et al. J. Clin. Invest.; published online March 1, 2013;
Contact: Ivan Maillard, University of Michigan, Ann Arbor, Mich.